Abstract: The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

Abstract: A display device includes a substrate that includes a display area and a non-display area, a display element layer disposed on the display area of the substrate, an opposing substrate that faces the substrate and the display element layer, a sealing member disposed on the non-display area and that couples the substrate and the opposing substrate, and a filler disposed between the substrate and the opposing substrate. A thickness of the filler varies in the range of 60% to 400% of a thickness of the sealing member.

Abstract: The present disclosure relates to a method and apparatus for generating a lane polyline by using a neural network model. The method according to an embodiment may extract a multi-scale image feature by using a base image obtained from at least one sensor loaded in a vehicle. According to the method, the multi-scale image feature is input to a first neural network model as input data and a BEV feature may be obtained as output data from the first neural network model. Also, according to the method, the BEV feature may be input to a second neural network model as input data and a polyline image with respect to a certain road may be obtained as output data from the second neural network model. In the present disclosure, a lane polyline obtained from the neural network may be utilized in vehicle control without going through an additional treatment process.

Abstract: The present invention relates to a composition for preventing or treating ischemia-reperfusion injury, the composition comprising an NADPH oxidase 1 (NOX1) inhibitor as an active ingredient, and more specifically, to a composition exhibiting prophylactic or therapeutic effects on ischemia reperfusion injury by suppressing the signaling of extracellular-signal-regulated kinase (ERK) by means of reactive oxygen species (ROS).